Who are Post - Vaccination's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pediarix, Shenlingcao Oral Liquid, Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis, Tice Bcg, IMOVAX Polio®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vaccination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Post - Vaccination — Competitive Intelligence Brief

Post - Vaccination (vaccination) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated Poliovirus Vaccine [EPC]. Area: Immunology.

marketed Inactivated Poliovirus Vaccine [EPC] Immune system Immunology Live · refreshed every 30 min

Target snapshot

Post - Vaccination (vaccination) — Pfizer.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Post - Vaccination TARGET	vaccination	Pfizer	marketed	Inactivated Poliovirus Vaccine [EPC]	Immune system
Pediarix	pediarix	Pfizer Inc.	marketed	vaccine	Immune system
Shenlingcao Oral Liquid	Shenlingcao Oral Liquid	West China Hospital	marketed	Traditional Chinese Medicine	Immune system
Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis	Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis	Sanofi Pasteur, a Sanofi Company	marketed	Vaccine	The vaccine targets the immune system to produce antibodies against tetanus, diphtheria, and pertussis toxins.
Tice Bcg	bcg	Pfizer	marketed	Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]	BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.
IMOVAX Polio®	IMOVAX Polio®	GlaxoSmithKline	phase 3	Inactivated poliovirus vaccine (IPV)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated Poliovirus Vaccine [EPC] class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Post - Vaccination — Competitive Intelligence Brief. https://druglandscape.com/ci/vaccination. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab